Epigenetic regulatory mechanism results in breast cancer drug resistance
A new finding from researchers at Memorial Sloan Kettering Cancer Center (New York, NY, USA) revealed that the PI3K pathway activates the ER pathway through an epigenetic mechanism using a protein called KMT2D. The discovery of this epigenetic link could guide future long-term therapeutic strategies.
Please sign in or register for FREE to view this content
Sign in to EpigenomicsNet
Register to EpigenomicsNet – the epigenetics and epigenomics network
EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.